

Dermatology Update 2008 Program as of April 4, 2008

	Thursday April 10		Friday April 11		Saturday April 12	
7am-9am	Ad. Board 7:00am – 9:00am Controversies in Conventional Acne Therapy <i>(by invitation)</i>		Ad. Board 7:00am – 9:00am Raptiva Restore Investigator Meeting <i>(by invitation)</i>	Ad. Board 7:00am – 9:00am The Practical Treatment of Atopic Dermatitis: A Global Perspective <i>(by invitation)</i>	Ad. Board 7:00am – 9:00am Professional Selling Workshop <i>(by invitation)</i>	Ad. Board 7:00am – 9:00am Linking the Product Profile and Clinical Benefits of Novel Psoriasis Treatment Options to the Efficient Management of your Psoriasis Patients in Practice <i>(by invitation)</i>
7:30am-9am	Chateau Buffet Breakfast		Chateau Buffet Breakfast		Chateau Buffet Breakfast	
9am-10am	Plenary Session 9:05am – 10:30am		Plenary Session 9:05am – 10:20am		Plenary Session 9:05am – 10:35am	
10am-11am	9:05 – 9:15 Opening Comments 9:15 – 9:45 Skin Therapy Update - <i>Stuart Maddin</i> 9:45 – 10:15 The New Immune System Targets in the Treatment of Psoriasis – The IL-12 and IL-23 Cytokine Family - <i>James Krueger</i> 10:15 – 10:30 Raptiva® in psoriasis: A trusted therapy for enduring disease clearance - <i>Chih-Ho Hong</i> 10:30 – 10:45 Q&A		9:05 – 9:20 The Future Management of Psoriasis - <i>Giampiero Girolomoni</i> 9:20 – 9:35 DermaDNA™: The Use of Mitochondrial DNA as a “Biosensor” for UVR Induced Skin Damage in relation to the genetic determination of skin type: Implications for Personalized Skin Care. - <i>Mark Birch-Machin</i> 9:35 – 9:50 Etanercept Treatment in Children and Adolescents with Plaque Psoriasis - <i>Richard Langley</i> 9:50 – 10:05 Biologics: What Can You Really Expect After the Initial Treatment? - <i>Yves Poulin</i> 10:05 – 10:20 Q&A		9:05 – 9:20 Skin Cancer Update in the Transplant Population - <i>Claas Ulrich</i> 9:20 – 9:35 TBA - <i>Mark Lebwohl</i> 9:35 – 9:50 Whither Goes IRM? - <i>Ted Rosen</i> 9:50 – 10:05 University to Private Practice: The Ethics of Professional Selling – <i>Cherie Ditre</i> 10:05 – 10:15 Canadian Skin Patient Alliance – <i>Christine Jackson</i> 10:15 – 10:30 Q&A	
11am-12pm	Clinical Trials Workshop 10:45am – 12:15pm <i>(by pre-registration)</i>		Open Session 10:30am – 12:00pm Cosmeceuticals - Practical Solutions for Common Problems		Open Session 10:50am – 12:05pm Getting to the Root of the Problem: <i>Delving into psoriasis, common comorbidities, and therapeutic options</i>	
12pm-1pm	SKI BREAK 10:45am – 3:00pm		SKI BREAK 12:05pm – 3:00pm		Ad. Board 12:15pm – 2:15pm Patient and Clinic Support: Defining Dermatology Needs <i>(by invitation)</i>	Ad. Board 12:15pm – 2:15pm Managing Moving Towards Optimal Topical Therapy for Psoriasis <i>(by invitation)</i>
1pm-2pm						
2pm-3pm						
3pm-4pm	Ad. Board 3:00pm – 5:00pm Workshop on Acne and Anti-Fungal <i>(by invitation)</i>	Ad. Board 3:00pm – 5:00pm Update in Pediculosis Management & Assessing Nycomed Dermatology Pipeline <i>(by invitation)</i>	Ad. Board 3:00pm – 5:00pm Challenging Cases in the Therapeutics of Psoriasis: A Female Dermatologist's Perspective <i>(by invitation)</i>		Plenary Session 2:30pm – 4:00pm 2:30 – 2:40 Ice & Hyperhidrosis – <i>Kevin Smith</i> 2:40 – 2:45 BTX & facial fillers - <i>Kevin Smith</i> 2:45 – 3:00 Management of Hair Loss in Women - <i>Jerry Shapiro</i> 3:00 – 3:15 The Burden of Psoriasis and Psoriatic Arthritis in Canada: Insights from the Psoriasis Knowledge in Canada (SKIN) Survey - <i>Chuck Lynde</i> 3:15 – 3:30 Realistic treatment option for persistent acne (2008)- <i>Jerry Tan</i> 3:30 – 3:45 Restoring natural-looking, long-lasting volume with Sculptra injectable poly-L-lactic acid - <i>Wayne Carey</i> 3:45 – 4:00 Q&A 4:00 – 4:10 Closing Comments	
4pm-5pm	Open Session 5:15pm – 6:30pm Novel Psoriasis Treatment Options: The Clinical Results of Targeting IL-12 and IL-23		Open Session 5:15pm – 6:30pm Practical Perspectives in a Biologic Era of Psoriatic Disease		Open Session 4:15pm – 5:30pm What's New in the Treatment of Non-Melanoma Skin Cancer?	
6pm-7pm	BC Wine Tasting Reception 6:30pm – 7:30pm				Closing Reception 5:30pm – 7:00pm	
7pm-8pm						
8pm -9pm	Ad. Board 7:00pm – 10:30pm ENBREL Advisory Board <i>(by invitation)</i>					

Novel Psoriasis Treatment Options: The Clinical Results of Targeting IL-12 and IL-23

Thursday April 10th, 2008

5:15pm to 6:30pm

Objectives:

- To investigate the current unmet medical needs that exist for effective therapies with limited toxicity and side effects
- To uncover whether the blocking of IL-12 and IL-23 with antibodies may lead to improvement in psoriasis outcomes
- To discuss the new clinical trial data on monoclonal antibodies targeted toward the IL-12 and IL-23 blockade in psoriasis

Cosmeceuticals – practical solutions for common problems

Friday April 11th, 2008

10:30am to 12:00pm

Chaired by Dr Jeffrey Dover with special Cdn panelists

Agenda:

Introduction - *Dr Lee Bansil PhD, P&G*

"Cosmeceuticals- practical solutions for common problems' – *Dr Jeffrey Dover*
Q&A

Canadian Panel discussion

Q&A and Wrap up

Practical Perspectives in a Biologic Era of Psoriatic DiseaseFriday April 11th, 2008

5:15pm to 6:30pm

Program Objectives:

Discuss, in a practical, case based approach:

- 1) Optimal management of "problem psoriasis"
- 2) Patient management issues pertaining to appropriate patient selection, screening and safety considerations when choosing a biologic therapy.

Dr. Marc Bourcier - (Moncton, NB) - Chair (10 mins)
Program introduction and objectives.

Dr. Marc Lebwohl - (New York, NY)

Topic: Problem Psoriasis (25mins)

Learning objectives:

- 1) Identify and learn how to effectively counsel your problem psoriasis patient
- 2) Discuss the role of systemic therapies in problem psoriasis
- 3) Discuss the role of biologic therapies in problem psoriasis
- 4) Discuss combination treatment strategies for these difficult (recalcitrant) patients

Dr. Richard Langley - (Halifax, NS)

Topic: Practical Aspects of Biologic Therapy in Psoriatic Disease – Safety Considerations (25 mins)

Learning objectives:

- 1) Identify potential safety aspects when considering biologic therapy
- 2) Develop a practical approach in managing patients on biologics with respect to the following clinical scenarios: vaccinations, pregnancy, infections, hepatitis and surgery considerations

Panel Q&A (15 mins) - facilitated by Dr. Bourcier

Getting to the Root of the Problem: *Delving into psoriasis, common comorbidities, and therapeutic options.*

**Saturday April 12th, 2008
10:45am to 12:00pm**

Objectives:

The accredited activity will be led by the national and international experts in dermatology and will shed light on the latest data with biological treatment to improve patient outcomes in moderate-to-severe plaque psoriasis. Following the symposium, participants should be able to: 1) describe and discuss the practical management of patients with moderate-to-severe plaque psoriasis; 2) discuss appropriate patient selection and patient counseling once a biologic is considered; and 3) identify and discuss the condition's common comorbidities and rationale for biologic therapy. The symposium is supported by an unrestricted educational grant by Schering-Plough Canada.

Faculty

1. Dr. Ronald B. Vender (Chair)

Associate Professor, McMaster University
Head of Dermatology, Department of Medicine
Dermatology Consultant, St. Joseph's Healthcare
Hamilton Civic Hospital
Hamilton, Ontario

2. Professor Giampiero Girolomoni

Professor of Dermatology
Head of the Department of Dermatology
University of Verona School of Medicine
Verona, Italy

3. Dr. Chih-Ho Hong

Clinical Assistant Professor, University of British Columbia
Diplomate, American Board of Dermatology
St. Paul's Hospital
Vancouver, BC

Agenda:

Practical considerations: *Risk versus benefit of biologics*

Dr. Ronald Vender

Bringing clarity to psoriasis: *Understanding the condition, its comorbidities, and rationale for biologic treatment*

Prof. Giampiero
Girolomoni

Starting from scratch: *Case studies of my first 10 psoriasis patients on biologic therapy*

Dr. Chih-Ho Hong

New Treatment Modalities for Non-Melanoma Skin Cancer

Saturday April 12th, 2008

4:15pm to 6:00pm

Program Objectives:

After attending the session, participants should be able to:

- Better understand the new approaches in the treatment of non-melanoma skin cancer
- Incorporate new approaches in the treatment of NMSC into their practice

Chair

Jason K. Rivers, MD, FRCPC

University of British Columbia, Pacific DermAesthetics,
Vancouver, BC

Faculty

Ted Rosen, MD

Baylor College of Medicine,
Houston, Texas

Claas Ulrich, MD

Skin Cancer Center Charité, Department of Dermatology, Venereology and Allergology,
Charité – University Medical Center Berlin, Germany

Agenda:

4:15 Introduction & Welcome

Jason K. Rivers, MD, FRCPC

4:45 Squamous Cell in-situ (Bowen's Disease)

Ted Rosen, MD

5:15 New Comparative Data in Actinic Keratosis

Claas Ulrich, MD

5:45 Q&A and Conclusion

Jason K. Rivers, MD, FRCPC